Pear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference

Rhea-AI Summary

Pear Therapeutics, traded as PEAR on Nasdaq, announced its participation in the Credit Suisse 31st Annual Healthcare Conference on November 8 in Rancho Palos Verdes, California. Corey McCann, M.D., Ph.D., will represent the company in an analyst-led fireside chat at 3:15 p.m. Pacific Time. A live audio webcast will be accessible on Pear's website and available for 30 days after the event. Pear Therapeutics is a leader in developing software-based medicines, known as prescription digital therapeutics (PDTs), with groundbreaking FDA approvals in substance use and chronic insomnia treatments.

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Credit Suisse 31^st Annual Healthcare Conference in Rancho Palos Verdes, California. Corey McCann, M.D., Ph.D., President and CEO, will represent the company in an analyst-led fireside chat at 3:15 p.m. Pacific Time on Tuesday, November 8.

A live audio webcast can be accessed by clicking here and will be made available in the Investors section of Pear’s website at www.peartherapeutics.com. A replay of the webcast will be available on Pear’s website for up to 30 days following the live presentation.

About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET^®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O^®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst^® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005909/en/

Media and Investors:

Meara Murphy

Senior Director, Corporate Communications

meara.murphy@peartherapeutics.com

Source: Pear Therapeutics, Inc.

FAQ

When will Pear Therapeutics participate in the Credit Suisse Annual Healthcare Conference?

Pear Therapeutics will participate in the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022.

Who will represent Pear Therapeutics at the conference?

Corey McCann, M.D., Ph.D., will represent Pear Therapeutics at the conference.

What time is Pear Therapeutics' presentation at the conference?

Pear Therapeutics' presentation will take place at 3:15 p.m. Pacific Time.

How can I access the Pear Therapeutics presentation?

The presentation can be accessed via a live audio webcast on Pear's website.

Will the Pear Therapeutics presentation be available later?

Yes, a replay of the presentation will be available on Pear's website for up to 30 days after the event.